Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
23 October, 2018 00:28 IST
Lupin launches generic Tobramycin inhalation solution in US
Source: IRIS | 14 Jun, 2018, 09.31AM
Comments  |  Post Comment

Pharma major Lupin announced the launch of its Tobramycin Inhalation Solution USP, having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Tobramycin Inhalation Solution USP, 300 mg/5 ml is the generic equivalent of Novartis Pharmaceuticals Corporation's Tobis300 mg/5 ml. It is indicated for the management of cystic fibrosis patients with P. aeruginosa.

Tobramycin Inhalation Solution USP, 300 mg/5 ml had annual sales of approximately USD 99 million in the US (IQVIA MAT April 2018).

Shares of the company gained Rs 27.95, or 3.27%, to trade at Rs 882.25. The total volume of shares traded was 23,258 at the BSE (9.19 a.m., Thursday).





Lupin Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Sensex ends 181 points lower; Nifty settles below 10,300 - 22-Oct-2018 16:06
Biocon, Mylan announce positive CHMP Opinion for Ogivri - 22-Oct-2018 10:28
Air cargo industry must grow 12.9% annually to achieve national aviation policy target: Study - 22-Oct-2018 10:05
RBI opens banking tap to ease liquidity crunch at NBFCs - 22-Oct-2018 10:01
Sensex rises near 100 points; Nifty above 10,300 - 22-Oct-2018 09:55
Lupin announces positive CHMP opinion for NaMuscla - 22-Oct-2018 09:51
Tejas Networks bags Rs 1.11 bn order from Sterlite Technologies - 22-Oct-2018 09:45
Alembic Pharma' JV completes USFDA inspection of Karakhadi unit - 22-Oct-2018 09:41
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer